WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million-March 2024-www.financetom.com

WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million

Jan 6, 2025 4:23 AM

Jan 6 (Reuters) - WuXi Biologics ( WXIBF ) said on

Monday its unit, WuXi Vaccines Ireland, will sell its vaccine

facility in Ireland to Merck ( MRK ) for about $500 million.

Previous page： Vedanta appoints John Slaven as CEO of aluminium business, Stephen Moore as Deputy CEO of Cairn Oil & Gas Next page： Prataap Snacks expects revenue from namkeen segment to rise from 15% to 22% by year-end, says MD & CEO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Vedanta appoints John Slaven as CEO of aluminium business, Stephen Moore as Deputy CEO of Cairn Oil & Gas

Aug 4, 2023

Vedanta's board of directors, in a meeting today, appointed John Slaven as the CEO of the company’s aluminium business while Stephen Russell Moore was designated as the Deputy CEO of the company's oil and gas exploration arm.

Prataap Snacks expects revenue from namkeen segment to rise from 15% to 22% by year-end, says MD & CEO

Aug 4, 2023

Prataap Snacks is looking at expanding to 2.5 million outlets from the present 2.1 million ones this year.

Applied Materials works to bring global suppliers to India

Aug 4, 2023

India is a key market for U.S.-based Applied Materials where the firm plans to invest $400 million over coming years in a new engineering centre in the tech hub of Bengaluru. The centre will focus on developing technology for chipmaking tools.

KEC International confident about strong order intake

Aug 4, 2023

KEC International announced the acquisition of new orders amounting to a staggering Rs 1,065 crore. These new orders span across different segments, illustrating the company's diverse capabilities and its strong foothold in multiple areas of the infrastructure industry.